Genenta Science 保证21.9M 用于推进癌症药物Temferon, 在脑肿瘤试验中表现出希望。 Genenta Science secures $21.9M to advance cancer drug Temferon, showing promise in brain tumor trials.

Genenta Science的生物技术公司已经从ENEA技术和生物医学获得2 000万欧元(2 190万美元)的资金,以扩大其癌症治疗研究,重点是转移性肾癌的Temferon。 Biotech company Genenta Science has secured €20 million ($21.9 million) in funding from ENEA Tech and Biomedical to expand its cancer treatment research, focusing on Temferon for metastatic kidney cancer. 投资支持正在进行的试验,旨在改善安全和效力。 The investment supports ongoing trials and aims to improve safety and efficacy. Genenta的Temferon在脑肿瘤试验中显示29%的存活率,比标准14%的存活率有了显著提高。 Genenta's Temferon has shown a 29% survival rate in a brain tumor trial, a significant improvement over the standard 14% survival rate.